Improving diagnosis and treatment of blood cancer

Adelaide researchers will use a $1 million Federal Government grant to improve the diagnosis and treatment of blood cancers, which kill 16 Australians every day.

The Centre for Cancer Biology (CCB), an alliance between UniSA and SA Pathology, has been awarded the funds as part of a $2.5 million national genomic project led by the Walter and Eliza Hall Institute.

An international team of researchers will use new technologies to cross-reference genomic data and speed up the diagnosis and treatment of blood, ovarian and breast cancers, thanks to the Medical Research Future Fund.

Section Head of the CCB Molecular Pathology Research Laboratory, Associate Professor Chris Hahn, said Adelaide researchers will focus on blood cancers, developing powerful new functional experiments to identify which genetic variants are harmful and which are benign.

“In Australia, about 17,000 people are diagnosed with blood cancers every year and we think that about 20 per cent of those carry a genetically inherited component. While we can efficiently and accurately identify thousands of genetic mutations or variants, what we don’t know is whether they cause cancer or not. This project will help us do that,” Assoc Prof Hahn said.

“There’s a term called ‘diagnostic odyssey’ where people can go for years not knowing what is causing their disease. By using state-of-the-art technologies, we will be able to measure the effect of all possible mutations within a gene and educate clinicians on how to interpret that data to improve patient treatment.

“It will speed up the diagnosis, save families a lot of stress, and the potential to save the medical system millions of dollars.”

Assoc Prof Hahn said by correctly classifying genetic mutations which cause cancer, clinicians will be able to provide drug-specific targeted treatments were available and better patient management including genetic counselling for the family.

“Some blood cancers are notoriously difficult to treat. In cases where there aren’t good drugs or where standard treatments have failed, haematologists may need to progress to bone marrow transplants.

“Knowing the genetic cause means they can then make an informed decision about whether family members are suitable donors, or whether they are also carriers of the predisposing mutation.

“Ultimately, we would like to be able to prevent diseases such as blood cancers. By accurately identifying whether individuals and families have a genetic predisposition, we may be able to correct that mutation down the track with gene therapy or gene editing approaches.”

Content from the University of South Australia media page. Note: Content has been edited for style and length.

Ritchelle Drilon

Website | + posts

Ritchelle is a Content Producer for Healthcare Channel, Australia’s premier resource of information for healthcare.

• Aged Care Transition Taskforce assembled to guide historic reform
• Study finds gaps in clinical trial data transparency for top medicines
• Retirement villages offer better quality of life for seniors: Study
• Digital aged care tool wins national innovation award